September 29, 2020
Norwegian Decision Forum for New Methods on September 21, 2020
On September 21, 2020, Decision Forum for New Methods was conducted, and minutes were published. The meeting considered six pharmaceuticals.

Five (5) decisions on introduction were made:

  • Sekukinumab (Cosentyx) for the treatment of non-radiographic axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) from February 01, 2021
  • Ozanimod (Zeposia) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from October 15, 2020
  • Ruksolitinib (Jakavi) for the treatment of disease-related splenomegaly or symptoms of myelofibrosis from October 15, 2020
  • Atezolizumab (Tecentriq) in combination with bevacizumab, paclitaxel and carboplatin for the treatment of non-small cell lung cancer that has EGFR mutation or is ALK-positive which is no longer successful with targeted treatment. The decision requires the use of the most affordable alternative to bevacizumab. This treatment can be used from October 01, 2020
  • Bevacizumab for the treatment of advanced cervical cancer and in case of recurrence of cervical cancer from October 01, 2020

One (1) non-introduction decision was made:

  • Telotristat (Xermelo) is not introduced for the treatment of diarrhea in malignant carcinoid syndrome. There is evidence of the effectiveness, but the long-term effectiveness is uncertain, and the price is too high

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)